基于模型的方法和创新的临床试验设计,以腺相关病毒载体基因疗法产品开发:白皮书
Amitava Mitra1, Mariam A Ahmed2, Rajesh Krishna3
1Clinical Pharmacology, Kura Oncology, Boston, Massachusetts, USA.
Clinical pharmacology and therapeutics
|June 14, 2023
概括
基于模型的药物开发 (MIDD) 提供了定量工具,以优化腺相关病毒 (AAV) 基因疗法的临床试验设计. 这种方法支持剂量选择,并加强了这些复杂的,拯救生命的治疗方法的开发.
科学领域:
- 基因治疗是一种基因疗法.
- 病毒载体技术是病毒载体技术.
- 药物开发 药物开发
背景情况:
- 使用病毒载体的基因疗法 (GT) 对严重疾病具有前景,最近获得了产品批准.
- 基因疗法基于阿诺相关病毒 (AAV) 载体的基因疗法是复杂的,需要专门的专业知识.
- 治疗不可逆转的效果和对罕见疾病的有限理解需要仔细评估好处与风险.
研究的目的:
- 探索基于模型的药物开发 (MIDD) 在基于AAV的基因治疗中的应用.
- 确定挑战,并为开发AAV基因疗法提出改进建议.
- 突出定量工具在优化临床开发中的作用.
主要方法:
- 对AAV基因疗法开发的集体经验的审查.
- 确定剂量选择,暴露-反应关系和研究设计中的挑战.
- 应用基于模型的药物开发 (MIDD) 原则.
主要成果:
- MIDD提供了一个框架,可以利用数据的总体进行决策.
- 定量工具可以支持剂量选择和优化临床试验设计.
- MIDD有助于对罕见疾病的终点选择和患者丰富策略.
结论:
- MIDD非常适合于基于AAV的新型基因疗法的合理开发.
- 解决剂量选择和研究设计方面的挑战对AAV GT至关重要.
- 进一步纳入MIDD工具可以加强这些变革性疗法的发展.
更多相关视频
04:43Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification
Published on: October 11, 2024
2.0K
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
4.6K
相关概念视频
Microorganisms in Medicine and Therapeutics
72
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
72
Gene Therapy
25.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.6K
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
